Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Tackling reproducibility in academic preclinical drug discovery

Nature Reviews Drug Discovery volume 14, pages 733–734 (2015)Cite this article

Subjects

Abstract

The reproducibility of biomedical research on novel drug targets has become suspect. Here, we highlight how drug discovery centres embedded in academic institutions, but with a translational imperative, can help address this reproducibility crisis.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dolgin, E. Drug discoverers chart path to tackling data irreproducibility. Nat. Rev. Drug Discov. 13, 875–876 (2014).

    Article  CAS  Google Scholar 

  2. Prinz, F., Schlange, T. & Asadullah, K. Believe it or not: how much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712 (2011).

    Article  CAS  Google Scholar 

  3. Errington, T. M. et al. An open investigation of the reproducibility of cancer biology research. eLife 3, http://dx.doi.org/10.7554/eLife.04333, (2014).

  4. Baell, J. & Walters, M. A. Chemical con artists foil drug discovery. Nature 513, 481–483 (2014).

    Article  CAS  Google Scholar 

  5. Arrowsmith, C. H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536–541 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Integrative Chemical Biology and Drug Discovery, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, 27599-7363, North Carolina, USA

    Stephen V. Frye & Emily A. Hull-Ryde

  2. Small Molecule Discovery Center, School of Pharmacy, University of California at San Francisco, 1700 4th Street, Box 2552, San Francisco, 94143, California, USA

    Michelle R. Arkin

  3. Structural Genomics Consortium, University of Toronto, Suite 700, MaRS South Tower, 101 College Street, Toronto, M5G 1L7, Ontario, Canada

    Cheryl H. Arrowsmith

  4. Department of Pharmacology, Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, 1205 LH, Nashville, 37232-0697, Tennessee, USA

    P. Jeffrey Conn

  5. ORIG3N, 27 Drydock Avenue, Boston, 02210, Massachusetts, USA

    Marcie A. Glicksman

  6. Johns Hopkins Drug Discovery, Johns Hopkins School of Medicine, Rangos Suite 277, 855 North Wolfe Street, Baltimore, 21205, Maryland, USA

    Barbara S. Slusher

Authors
  1. Stephen V. Frye
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle R. Arkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheryl H. Arrowsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Jeffrey Conn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marcie A. Glicksman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emily A. Hull-Ryde
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Barbara S. Slusher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen V. Frye.

Ethics declarations

Competing interests

The authors are either members or board members of the Academic Drug Discovery Consortium.

Related links

Related links

FURTHER INFORMATION

Academic Drug Discovery Consortium

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frye, S., Arkin, M., Arrowsmith, C. et al. Tackling reproducibility in academic preclinical drug discovery. Nat Rev Drug Discov 14, 733–734 (2015). https://doi.org/10.1038/nrd4737

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4737

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research